These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
12. Hoffmann-LaRoche announces international compassionate treatment program for saquinavir. J Int Assoc Physicians AIDS Care; 1995 Jun; 1(5):32-4. PubMed ID: 11362607 [TBL] [Abstract][Full Text] [Related]
13. Roche investigators say Invirase does not cause cross-resistance to other protease inhibitors. Baker R BETA; 1995 Sep; ():5. PubMed ID: 11362895 [TBL] [Abstract][Full Text] [Related]
14. Saquinavir (Roche protease inhibitor) at higher doses. AIDS Treat News; 1995 Sep; (no 231):5. PubMed ID: 11362870 [TBL] [Abstract][Full Text] [Related]
15. No tease this time--pros and cons of a long-awaited anti-HIV drug. Chang HE Posit Aware; 1996; 7(1):18-20. PubMed ID: 11363118 [TBL] [Abstract][Full Text] [Related]
16. FDA approves 3TC and saquinavir. Food and Drug Administration. Baker R BETA; 1995 Dec; ():5, 9. PubMed ID: 11363011 [TBL] [Abstract][Full Text] [Related]
17. FDA antiviral advisory hearings on lamivudine (Epivir, 3TC), saquinavir (Invirase), stavudine (Zerit, d4T), November 6-8. Food and Drug Administration. AIDS Treat News; 1995 Oct; (no 233):4-5. PubMed ID: 11363038 [TBL] [Abstract][Full Text] [Related]
18. Why the old saquinavir (Invirase) may be bad for your health. Vazquez E Posit Aware; 1997; 8(4):28-31. PubMed ID: 11364485 [TBL] [Abstract][Full Text] [Related]
19. Invirase program expands. AIDS Patient Care; 1995 Dec; 9(6):305. PubMed ID: 11361444 [No Abstract] [Full Text] [Related]